RENAAL

RENAAL

Nephrology A clinical trial–Reduction in Endpoints in patients with Non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan. See Losartan.
Mentioned in ?
References in periodicals archive ?
Post hoc analyses of a subset of participants in the RENAAL (Reduction of Endpoints in Non Insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan) trial compared 24-h urine protein, 24-h urine albumin, and albumin:creatinine ratios for their association with renal function decline (51).
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al; for the RENAAL Study Investigators.
The 21 clinical trials analyzed were IDNT, RENAAL, ALLHAT, LIFE, INVEST, ANBP-2, SCOPE, VALUE, JMIC-B, ASCOT-BPLA, MOSES, JIKEI, ADVANCE, HYVET, ONTARGET, TRANSCEND, PROFESS, ACCOMPLISH, KYOTO, NAVIGATOR.
The Irbesartan Diabetic Nephropathy Trial and the RENAAL (Reduction of Endpoints in NIDDM [noninsulin-dependent diabetes mellitus] with the Angiotensin II Antagonist Losartan) trial demonstrated that, independent of BP reduction, ARB therapy was superior to non-ACEI, non-ARB, or calcium channel blocker (CCB) (amlodipine) therapy in slowing the progression of nephropathy (24, 25).
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
This approval is based on the results from the international clinical trial called RENAAL (Reduction of Endpoint in NIDDM with A-II Antagonist Losartan), which covered 1,513 type-2 diabetics (including 96 Japanese patients).
Study evaluated effects of Cozaar beyond blood pressure lowering This randomized, placebo-controlled study called RENAAL (Reduction of Endpoints in Non-Insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan) followed patients for an average of 3.
Many physicians, however, use lower doses in order to lessen the hyperkalemia risk, despite outcome studies such as RENAAL, IDNT and IRMA2 not showing that lower doses of ARBs provide this renoprotective benefit," added Dr.
Bakris GL, Weir MR, Shanifar S, et al, for the RENAAL Study Group.
Like SOLV-D, 4S, LIFE and RENAAL, this study, too, advances our understanding of the role that pharmaceutical innovations can have and answers an important outstanding question as only a clinical outcomes trial can.
In this analysis of the RENAAL trial the blood pressure response to an ARB (losartan) was dissociated from the albuminuria response.